MAPK3 and Alzheimer disease: In the APP/PS1 mouse model, subchronic therapy with apigenin reduces β-CTF, BACE, and β-amyloid deposition and improves BDNF expression, increasing memory and synaptic plasticity through the ERK1/2/CREB-mediated inhibition of AD [140].